Leukemia & Lymphoma
Volume 63, 2022 - Issue 12
Open access
1,227
Views
0
CrossRef citations to date
0
Altmetric
Original Articles
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design
Anita Kumara Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesCorrespondence[email protected]
View further author information
, View further author information
Carla Casulob Department of Medicine, Wilmot Cancer Institute, University of Rochester, Rochester, United StatesView further author information
, Erel Joffea Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United States
https://orcid.org/0000-0002-7883-289XView further author information
John Gerecitanoa Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
, Alison Moskowitza Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
, Anas Younesa Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
, Pamela Drullinskya Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
, Esther Drillc Epidemiology and Biostatistics, Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
, Morgan Chomaa Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
, Clare Grievea Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
, Ashlee Josepha Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United States
https://orcid.org/0000-0003-1699-5666View further author information
Leana Laraquea Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
, Dylan Schicka Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
, Andrew Zelenetza Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United States
https://orcid.org/0000-0003-1403-6883View further author information
Paul Hamlina Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United StatesView further author information
show all
Pages 2889-2896
|
Received 28 Mar 2022, Accepted 26 Jul 2022, Published online: 16 Aug 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.